US FDA approves AstraZeneca’s needle-free nasal spray, FluMist …
WEB2 days ago · Cambridge, UK. Monday, September 23, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical company, announced that FluMist has been approved in the US as the only self-administered influenza vaccine. FluMist, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or administered by a ...
US FDA approves anti-CD38 therapy, Sarclisa in combo with …
WEB1 day ago · The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant ...
EU committee recommends approval of AstraZeneca’s Fasenra to …
WEB1 day ago · AstraZeneca, global, science-led biopharmaceutical company, announced that its Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a ...
Teva Pharma announces long term efficacy and safety of …
WEB1 day ago · Teva Pharmaceutical Industries Ltd., a global pharmaceutical leader, announced that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients with tardive dyskinesia (TD) was associated with long term improvement of TD ...
Astellas Pharma announces US FDA listing of DIGITIVA for the …
WEB5 days ago · Tokyo. Friday, September 20, 2024, 11:00 Hrs [IST] Astellas Pharma Inc. announced that DIGITIVA, a non-invasive digital health solution for heart failure management, has been listed with the US Food and Drug Administration (FDA). DIGITIVA is classified as a Class I Software as a Medical Device (SaMD) and is exempt from 510 (k) premarket submission.
News - Pharmabiz.com
WEBSep 18, 2024 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing.
Pfizer, BioNTech receive US FDA approval & authorization for …
WEBSaturday, August 24, 2024, 09:00 Hrs [IST] Pfizer Inc. and BioNTech SE announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY (Covid-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 …
Boehringer Ingelheim’s Cyltezo to treat multiple chronic …
WEBFriday, May 3, 2024, 11:00 Hrs [IST] Boehringer Ingelheim Group, one of the largest producers of biologic medicines in the world, announced that the US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's interchangeable biosimilar to Humira (adalimumab), to ...
AstraZeneca completes acquisition of clinical-stage biotech …
WEBJul 16, 2024 · Cambridge, UK. Tuesday, July 16, 2024, 10:00 Hrs [IST] AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on ...
Takeda’s vedolizumab receives US FDA approval to treat …
WEBApr 20, 2024 · Osaka, Japan. Saturday, April 20, 2024, 16:00 Hrs [IST] Takeda announced that the US FDA has approved Entyvio (vedolizumab) subcutaneous administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio. The subcutaneous administration of …